MTOR and pancreatic neoplasm: Nevertheless, the response rate of 3/5 seen in the present study appears greater than that recently reported for other molecular targeted agents in primary pancreatic cancer xenografts (Rubio-Viqueira et al, 2006), suggesting that dual PI3K/mTor inhibitors like NVP-BEZ235 might have useful anticancer effects in pancreatic cancer patients.